BNP and ANP Peptides as Screening Tools for Hidden Heart Dysfunction
Brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP) show promise as blood markers for detecting left ventricular dysfunction, even in patients without symptoms.
Quick Facts
What This Study Found
ANP, BNP, and cGMP were compared as screening markers for asymptomatic and symptomatic left ventricular dysfunction, with potential utility for early detection.
Key Numbers
How They Did This
Cross-sectional study directly comparing plasma ANP, BNP, and cGMP levels in patients with asymptomatic versus symptomatic left ventricular dysfunction to evaluate their screening potential.
Why This Research Matters
Detecting heart dysfunction before symptoms appear allows earlier treatment that can prevent heart failure progression. Simple blood markers like BNP could enable population-wide screening.
The Bigger Picture
This study contributed to establishing BNP as a clinical biomarker for heart failure — it's now one of the most widely used blood tests in cardiology, ordered millions of times annually worldwide.
What This Study Doesn't Tell Us
Cross-sectional design limits ability to determine predictive value over time. Abstract doesn't detail sensitivity/specificity values or sample sizes.
Questions This Raises
- ?Which natriuretic peptide provides the best screening accuracy for asymptomatic heart dysfunction?
- ?At what threshold levels should screening be considered positive?
Trust & Context
- Key Stat:
- Screening for hidden heart disease ANP, BNP, and cGMP compared as blood markers to detect left ventricular dysfunction before symptoms develop
- Evidence Grade:
- Moderate clinical evidence from a comparative biomarker study. Cross-sectional design provides diagnostic but not prognostic data.
- Study Age:
- Published in 1996, this is an early study in natriuretic peptide biomarker research. BNP testing has since become standard clinical practice.
- Original Title:
- Natriuretic peptides and cyclic guanosine 3',5'-monophosphate in asymptomatic and symptomatic left ventricular dysfunction.
- Published In:
- Heart (British Cardiac Society), 76(2), 129-36 (1996)
- Authors:
- Friedl, W(2), Mair, J(2), Thomas, S(2), Pichler, M, Puschendorf, B
- Database ID:
- RPEP-00361
Evidence Hierarchy
A snapshot of a population at one point in time.
What do these levels mean? →Frequently Asked Questions
What are natriuretic peptides?
Natriuretic peptides (ANP and BNP) are hormones released by the heart when it's under stress or stretched. Higher blood levels indicate the heart is working harder than normal, making them useful markers for heart dysfunction.
Why screen for asymptomatic heart dysfunction?
Many people have weakened heart function without knowing it. Early detection allows treatment with medications like ACE inhibitors that can slow or prevent progression to full heart failure, significantly improving outcomes.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00361APA
Friedl, W; Mair, J; Thomas, S; Pichler, M; Puschendorf, B. (1996). Natriuretic peptides and cyclic guanosine 3',5'-monophosphate in asymptomatic and symptomatic left ventricular dysfunction.. Heart (British Cardiac Society), 76(2), 129-36.
MLA
Friedl, W, et al. "Natriuretic peptides and cyclic guanosine 3',5'-monophosphate in asymptomatic and symptomatic left ventricular dysfunction.." Heart (British Cardiac Society), 1996.
RethinkPeptides
RethinkPeptides Research Database. "Natriuretic peptides and cyclic guanosine 3',5'-monophosphat..." RPEP-00361. Retrieved from https://rethinkpeptides.com/research/friedl-1996-natriuretic-peptides-and-cyclic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.